Regeneron Pharmaceuticals Inc (REGN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $98.84B
Last updated: Nov 17, 2026 at 11:06 AM ET
Regeneron Pharmaceuticals Inc (REGN) Stock Forecast
Analysts expect Regeneron Pharmaceuticals (REGN) to earn $68.75 per share in the fiscal year ending Dec 31, 2026, on revenue of $18.78B. Of 28 analysts, 19 rate the stock Buy or Strong Buy, 8 Hold and 1 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 23 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 28 ratings average 2.25, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 68% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 4 | 14.3% |
| Buy | 15 | 53.6% |
| Hold | 8 | 28.6% |
| Sell | 0 | 0.0% |
| Strong Sell | 1 | 3.6% |
- Consensus
- Buy
- Total analysts
- 28
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus falls 9.6% and revenue estimates rise 7.3%.
- Fiscal year ending Dec 31, 2026
- $68.75
- EPS consensus, revenue $18.78B
- Fiscal year ending Dec 31, 2027
- $62.12
- EPS consensus, revenue $20.15B
- Next report
- Jan 28, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $68.75 | $61.35 to $74.53 | 25 | $18.78B | $17.82B to $19.49B | 25 |
| Dec 31, 2027 | $62.12 | $54.89 to $73.76 | 10 | $20.15B | $17.31B to $21.66B | 24 |
Quarterly Estimates
The EPS consensus falls from $26.27 for the quarter ending Dec 31, 2026 to $15.89 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $26.27 | $17.35 to $31.96 | 25 | $5.97B | $4.71B to $6.80B | 23 |
| Mar 31, 2027 | $15.89 | $12.90 to $18.80 | 9 | $4.60B | $4.11B to $4.85B | 8 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 35 upward and 1 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 23 | 0 |
| Fiscal year ending Dec 31, 2027 | 5 | 1 |
| Quarter ending Mar 31, 2027 | 7 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 29.7% from $53.01.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $68.75 | $68.75 | $56.52 | $53.80 | $53.01 | +29.7% |
| Fiscal year ending Dec 31, 2027 | $62.12 | $62.12 | $50.63 | $50.38 | $50.40 | +23.3% |
| Quarter ending Mar 31, 2027 | $15.89 | $15.89 | $12.73 | $13.12 | $13.12 | +21.1% |
Frequently Asked Questions About REGN
What is the REGN stock forecast?
Consensus analyst estimates put Regeneron Pharmaceuticals's EPS at $68.75 for the fiscal year ending Dec 31, 2026, on revenue of $18.78B. The consensus rating from 28 analysts is Buy.
How do analysts rate REGN stock?
Of 28 analysts covering Regeneron Pharmaceuticals, 4 rate it Strong Buy, 15 Buy, 8 Hold, 0 Sell and 1 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from REGN next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $68.75, with estimates from $61.35 to $74.53 from 25 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $62.12, with estimates from $54.89 to $73.76 from 10 analysts.
What revenue do analysts expect from Regeneron Pharmaceuticals next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $18.78B, with estimates from $17.82B to $19.49B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $20.15B, with estimates from $17.31B to $21.66B.
How many analysts cover REGN?
28 analysts rate Regeneron Pharmaceuticals stock, and 25 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
REGN pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts